Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.667910
Title: Clinical effectiveness of the angiotensin converting enzyme inhibitor, Ramipril, in patients with intermittent claudication : randomised, double-blind, placebo-controlled trial
Author: Shahin, Yousef
ISNI:       0000 0004 5363 8489
Awarding Body: Cardiff University
Current Institution: Cardiff University
Date of Award: 2015
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
Background: The HOPE trial showed that ramipril reduced cardiovascular morbidity and mortality in patients with peripheral arterial disease (PAD). However, evidence regarding the effect of angiotensin converting enzyme (ACE) inhibitors on walking distance, ankle brachial pressure index (ABPI), arterial stiffness and quality of life (QoL) in this group of patients is limited. Objective: The aim of this study is to investigate ACE inhibitors effect on clinical parameters of PAD, arterial stiffness and QoL in patients with intermittent claudication (IC). Methods: 33 patients (25 males, mean age: 65+/-7.8) with IC (Fontaine stage II or higher) were randomised to receive ramipril (5 mg once daily for 2 weeks increased to 10 mg once daily for 22 weeks, n=14) or placebo (n=19) for 24 weeks in a double-blind study. Walking distance was assessed using a standard laboratory treadmill test (2.5 km/hr at 10% incline). ABPI was assessed pre (r-ABPI) and post-exercise (t-ABPI). Arterial stiffness indices were measured using the SphygmoCor device. Results: After 24 weeks, ramipril improved maximum treadmill walking distance; adjusted mean change difference (95% confidence interval); by 130.5 (61.8 to 199.2) m longer than placebo (P=0.001), improved treadmill intermittent claudication distance by 121.9 (55.9 to 187.8) m longer than placebo (P=0.001) and improved patient reported walking distance by 159 (5.5 to 313) m compared to placebo (P=0.040). Ramipril reduced carotid femoral pulse wave velocity (a measure of arterial stiffness) by -1.47 (-2.4 to -0.57) m/s compared to placebo (P=0.002). However, r-ABPI and t-ABPI minimally changed in both groups (Ramipril 0.02 (-0.08 to 0.11)) vs. placebo 0.03 (-0.05 to 0.10, P=0.830) and (Ramipril 0.04 (-0.04 to 0.12)) vs. placebo 0.02 (-0.04 to 0.09, P=0.720), respectively. Ramipril had a slight insignificant effect on QoL physical domains compared to placebo. Conclusion: Ramipril improves walking distance in patients with IC; however, this improvement is not related to improvement in ABPI but might be due to ramipril ability to reduce arterial stiffness. ACE inhibitors effect on QoL needs to be validated in a larger randomised controlled trial.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.667910  DOI: Not available
Keywords: R Medicine (General)
Share: